Yihan Mei and Runxia Gu*
The field of cancer immunotherapy has witnessed remarkable advancements over the past decade, transforming the landscape of cancer treatment. Our recent publication in experimental hematology and oncology provides critical insights into the specific profile of tumor-reactive T cells in the bone marrow of Acute Myeloid Leukemia (AML) [1]. This commentary aims to review the key findings of the study and discuss their implications for future research and clinical applications.
PDFShare this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report
